

## Case Study – I

### Stage IV Melanoma 57 year old male patient

Clinical History	
Jan '16	<b>Diagnosis: Malignant Melanoma</b>
Aug '16	Ungual Lesion Excision
Dec '16	<b>PET-CT, USG: Progression</b> Lymph Node Excision
Jan – Feb '17	Radiotherapy
Mar '17	Lymph Node Excision
Mar '17	<b>PET-CT: Progression</b>

exacta® rationale for therapy selection		
Gene / Pathway / Analysis	Feature	Therapeutic Implication
KIT, PDGFRA	Overexpression	Imatinib
TYMS	Overexpression	5-Fluorouracil
MMP	Overexpression	Doxycycline
EMT, MET	Upregulation	Atorvastatin
WNT	Upregulation	Quercetin
Cell Cycle	Upregulation	Curcumin
AR	Positive (IHC)	Bicalutamid

## Benefit from exacta® – recommended therapy

**before**

Cancer had progressed following 4 lines of therapy.

**after**

Administration of exacta®: recommended therapy led to regression of cancer.

**day 0**

**day 31**